Cesamet (nabilone)

News alerts, weekly reports and conference planners

Company:

Bausch Health, Viatris

Drug class:

Cannabinoid receptor 1 agonist

‹

›

over1year

Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder (clinicaltrials.gov)

P1/2, N=0, Withdrawn, New York State Psychiatric Institute | N=60 --> 0 | Trial completion date: Jul 2026 --> May 2024 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2026 --> May 2024

over 1 year ago

Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date

Cesamet (nabilone)

2years

Effect of PP-01 on Cannabis Withdrawal Syndrome (clinicaltrials.gov)

P2, N=234, Completed, PleoPharma, Inc. | Active, not recruiting --> Completed

2 years ago

Trial completion

Cesamet (nabilone)

2years

DISCO-POT: DIalysis Symptom COntrol-Pruritus Outcome Trial (clinicaltrials.gov)

P3, N=14, Completed, University of Manitoba | Recruiting --> Completed

2 years ago

Trial completion

Cesamet (nabilone)

5years

Cannabis and its Constituents for Cancer: History, Biogenesis, Chemistry and Pharmacological Activities. (PubMed, Pharmacol Res)

Cannabinoid based products such as dronabinol, nabilone, nabiximols, and epidyolex are now approved for medical use in cancer patients. How cannabis and its constituents exert anticancer activities is discussed in this article. We also discuss areas that require attention and more extensive research.

5 years ago

Review • Journal

AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)

Cesamet (nabilone) • Epidiolex (cannabidiol) • dronabinol oral